Keele, UK: Cobra Biomanufacturing Plc (AIM: CBF), the international manufacturer of biopharmaceuticals, today announces that it has signed an agreement with ViroMed Co., Ltd. in Korea to produce VM206RY, a plasmid DNA treatment for tumours expressing Her2/neu (breast, ovarian, pancreatic, and stomach cancers). Under the agreement, Cobrabio will produce ViroMed’s Master Cell Bank and GMP-grade VM206RY for clinical trials which will be held in Korea and in the United States.
Simon Saxby, Chief Executive of Cobra Biomanufacturing said:
“We are delighted to continue our partnership with ViroMed. In a recent ViroMed project, Cobrabio demonstrated that our commitment to world class science, cGMP quality compliance and customer service provides the additional resources that leading biotech companies such as ViroMed require to drive their research and development programmes forward. ViroMed is Cobra’s first client in Asia and we are pleased to extend our services to this fast-growing life sciences market.”
Dr. Sunyoung Kim, CEO of ViroMed Co., Ltd. said:
“We are pleased to extend our relationship with Cobrabio to our VM206RY plasmid project. ViroMed is a rapidly expanding company with a growing pipeline of products in development and it is vital that we work with partners who can match our scientific expertise as well as our commitment to quality."
- ENDS -